In this episode of Biotalk podcast, Josh Hamermesh, Vice President of Locust Walk interviews Bradley Campbell, President & COO of Amicus Therapeutics. Amicus is very much at the forefront developing and commercializing important therapies to treat a range of devastating rare and orphan diseases. In fact, this has been an eventful and exciting week at Amicus as the company announced the launch of Galafold in the UK. Galafold is the first oral treatment as well as the first precision medicine product for patients with Fabry’s Disease patients.
<iframe width="450" height="450" scrolling="no" frameborder="no" src="https://w.soundcloud.com/player/?url=https%3A//api.soundcloud.com/tracks/314258108&auto_play=false&hide_related=false&show_comments=true&show_user=true&show_reposts=false&visual=true"></iframe>
